Glyko Biomedical launches lysosomal screening test:
This article was originally published in Clinica
Glyko Biomedical (US/Canada) has launched a lysosomal disorder screening in the US. The fluorophore-assisted carbohydrate electrophoresis (FACE) system is designed to highlight the characteristic banding patterns associated with the 25 or so lysosomal diseases that cause neuromuscular and intellectual impairment. The kit uses urine samples. Lysosomal disorders affect one in 2,000 at birth and in some cases lead to childhood death. Glyko is offering a screening service during the early marketing phase of the launch.